{
  "name": "Proportion of sodium-glucose co-transporter 2 (SGLT-2) inhibitors (including combination products) not prescribed as generic dapagliflozin tablets",
  "title": "Percentage SGLT-2 inhibitors items not prescribed as generic dapagliflozin tablets",
  "description": "Percentage SGLT-2 inhibitors items not prescribed as generic dapagliflozin tablets",
  "numerator_short": "SGLT-2 inhibitors items not prescribed as generic dapagliflozin tablets",
  "denominator_short": "SGLT-2 inhibitors items",
  "y_label": "Percentage SGLT-2 inhibitors items not prescribed as generic dapagliflozin tablets",
  "why_it_matters": [
    "<p>Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor commonly prescribed in type 2 diabetes, the treatment of chronic heart failure, and chronic kidney disease.</p>",
    "<p>Dapagliflozin lost its patent in August 2025.  From September 2025 the NHS tariff price is likely to fall, as it will be <a href='https://cpe.org.uk/our-news/dapagliflozin-tablets-changes-to-reimbursement-from-september-2025/' target='_Blank'>",
    "based on the generic price</a>, rather than the branded product.",
    "<a href='https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#drug-treatment' target='_Blank'> NICE guidance on the treatment of diabetes states that</a> <i>if 2 drugs in the same class are appropriate, choose the option ",
    "with the lowest acquisition cost</i>.",
    " Dapagliflozin is likely to have cost-saving opportunities when compared with other SGLT-2s.<p>",
    "<p><b>Please note:</b> OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' ",
    "and therefore in this case we show the proportion of SGLT-2 inhibitors which are NOT prescribed as generic dapagliflozin tablets."
  ],
  "tags": [
    "diabetes",
    "core",
    "cost"
  ],
  "url": null,
  "is_percentage": true,
  "is_cost_based": false,
  "low_is_good": true,
  "numerator_type": "custom",
  "numerator_columns": "SUM(p.items) AS numerator",
  "numerator_from": [
    "{hscic}.normalised_prescribing p ",
    "INNER JOIN {dmd}.vmp vmp ON CONCAT(SUBSTR(p.bnf_code,0,9),'AA', SUBSTR(p.bnf_code,-2), SUBSTR(p.bnf_code,-2)) = vmp.bnf_code -- joins prescribing data to vmp table using generic BNF code \n",
    "INNER JOIN {dmd}.vpi AS vpi ON vmp.id = vpi.vmp -- joins vmp to vpi table to get ingredient strengths (strnt_nmrtr_val) \n",
    "INNER JOIN {dmd}.ont AS ont ON vmp.id = ont.vmp -- joins vmp to ont table to get formulation codes \n",
    "INNER JOIN {dmd}.ontformroute AS route ON ont.form = route.cd -- joins ont table to ontform table to get formulation names "
  ],
  "numerator_where": [
    "(vpi.ing = 783086004 AND NOT(LEFT(p.bnf_code,11) ='0601023AGAA' AND route.descr ='tablet.oral')) --Dapagliflozin propanediol monohydrate (except generic tablets for non-combination) \n",
    "OR vpi.ing = 725664009 --Canagliflozin hemihydrate \n",
    "OR vpi.ing = 703894008 --Empagliflozin\n", 
    "OR vpi.ing = 1162393006 --Ertugliflozin L-pyroglutamic acid"
  ],
  "denominator_type": "custom",
  "denominator_columns": "SUM(p.items) AS denominator",
  "denominator_from": [
    "{hscic}.normalised_prescribing p ",
    "INNER JOIN {dmd}.vmp vmp ON CONCAT(SUBSTR(p.bnf_code,0,9),'AA', SUBSTR(p.bnf_code,-2), SUBSTR(p.bnf_code,-2)) = vmp.bnf_code -- joins prescribing data to vmp table using generic BNF code \n",
    "INNER JOIN {dmd}.vpi AS vpi ON vmp.id = vpi.vmp -- joins vmp to vpi table to get ingredient strengths (strnt_nmrtr_val) \n"
  ],
  "denominator_where": [
    "vpi.ing IN (725664009,783086004,703894008,1162393006) --Canagliflozin hemihydrate, Dapagliflozin propanediol monohydrate, Empagliflozin, Ertugliflozin L-pyroglutamic acid \n"
  ], 
"authored_by": "richard.croker@phc.ox.ac.uk",
  "checked_by": "andrew.brown@phc.ox.ac.uk",
  "date_reviewed": "2025-08-18",
  "next_review": "2027-08-18",
  "measure_complexity": "low",
  "measure_type": "dmd",
  "radar_exclude": false
}
